InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,615.35
(
0.55%
)
US TECH 100
19,804.00
(
0.64%
)
Dow Jones
40,000.90
(
0.62%
)
Brent Oil
84.57
(
0.00%
)
Bitcoin
60,153.26
(
1.55%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120032
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Biowatch post# 2023

Monday, 11/27/2006 1:44:28 PM

Monday, November 27, 2006 1:44:28 PM

Post# of 19309
>when I said that GTCB fell on its face before, I was referring to when the FDA asked them for more clinical trial data and then GENZ abandoned them. I don't remember the name of the person I saw speak, and I'm pretty sure he's not there anymore.<

Whoever it was you saw, the person who was held responsible for the failure of GTC’s original ATryn program in CABG was the then-CEO Sandra Nusinoff Lehrman, who was canned in May, 2001. Lehrman is an MD with a background in AIDS research who probably never should have been the CEO of GTC.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up